Vanda Pharmaceuticals | VNDA - DEBITO





DEBITO Cambiamento Data
Acadia Pharmaceuticals USD 54.81M 1.48M 2025-09
Agios Pharmaceuticals USD 44.52M 4.24M 2025-09
Akebia Therapeutics USD 46.51M 7.82M 2025-03
Alnylam Pharmaceuticals USD 1.31B 11.39M 2025-09
Anika Therapeutics USD 0 0 2025-03
Arrowhead Research USD 366.28M 13.25M 2025-09
AstraZeneca USD 32.63B 207M 2025-09
Bristol-Myers Squibb USD 51.04B 112M 2025-09
Eli Lilly USD 42.51B 2.6B 2025-09
Enanta Pharmaceuticals USD 1.35M 0 2024-12
Esperion Therapeutics USD 262.92M 1.76M 2024-09
Halozyme Therapeutics USD 1.51B 1.66M 2025-09
Heron Therapeutics USD 149.65M 157K 2024-09
Insmed USD 727.89M 163.33M 2025-12
J&J USD 45.8B 4.97B 2025-09
Lexicon Pharmaceuticals USD 99.26M 493K 2023-09
Ligand Pharmaceuticals USD 451M 445.26M 2025-09
Merck USD 41.37B 5.97B 2025-09
Minerva Neurosciences USD 0 0 2024-09
Moderna USD 734M 7M 2025-09
Novartis USD 32.02B 615M 2025-09
Pfizer USD 60.85B 78M 2025-09
PTC Therapeutics USD 286.32M 306K 2025-09
Puma Biotechnology USD 89.06M 55.07M 2024-06
Sangamo BioSciences USD 0 0 2022-06
Sanofi EUR 21.76B 530M 2025-09
Takeda JPY 4.85T 208B 2025-12
Teva Pharmaceutical Industries USD 17.07B 450M 2025-09
Ultragenyx Pharmaceutical USD 33.83M 2.46M 2025-09
Vanda Pharmaceuticals USD 4.96M 4.96M 2024-12
Veracyte USD 40.45M 10.19M 2025-09